All In Biotech

NDA 216513 · Medunik

Pheburane

Sodium Phenylbutyrate · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jun 17, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

76

17 Phase 3, 5 recruiting

FAERS reports

177

122 serious, 46 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 17, 2026.

PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Limitations of Use Episodes of acute hyperammonemia may occur in patients while on PHEBURANE. PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. PHEBURANE is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). ( 1 ) Limitations of Use PHEBURANE is not indicated for the treatment of acute hyperammonemia. ( 1 )

Mechanism: Sodium phenylbutyrate is a pro-drug and is metabolized to phenylacetate. Phenylacetate is a metabolically-active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 17, 2022 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • PHEBURANE · SODIUM PHENYLBUTYRATE 84GM/BOT · PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenylbutyrate" as an intervention, any sponsor and status, largest first.

All 76 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death24
  • off label use21
  • hyperammonaemia20
  • nausea20
  • diarrhoea18
  • decreased appetite16
  • ammonia increased13
  • vomiting13
  • product use complaint12
  • retching12
  • drug ineffective11
  • fatigue10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20082
20094
20105
20113
201215
20134
20146
20158
20168
20179
20182
20194
20204
20217
202210
202330
202424
202521
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pheburane (Sodium Phenylbutyrate)

2024 spending

$488K

Beneficiaries

n/a

15 claims

Per beneficiary

n/a

$26.70 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$487,856

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 68 on PubMed

Sponsor: Medunik

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.